FLT3 and acute myeloid leukemia: For instance, AML with FLT3 mutations is an example of a subtype in which treatment with FLT3 inhibitors, although promising, is not completely efficient due to the activation of target-dependent mechanisms (acquisition of point mutations in the kinase domain) reducing enzyme-inhibitor binding or through target-independent mechanisms and leading to primary or acquired resistance.